+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Kaposis sarcoma with IL-12

Treatment of Kaposis sarcoma with IL-12

Official Gazette of the United States Patent & Trademark Office Patents 1260(4), July 23

Methods are provided for using IL-12 to treat Kaposi's sarcoma (KS), particularly AIDS-associated KS.

(PDF 0-2 workdays service: $29.90)

Accession: 035980515

Download citation: RISBibTeXText

Related references

Detection of Kaposis sarcoma associated herpesvirus DNA by in situ hybridization in Kaposis sarcoma and posttransplant squamous lesions Evidence for infection of both Kaposis sarcoma tissue and squamous epithelium. Modern Pathology 9(1): 42A, 1996

Surgery in the treatment of Kaposis sarcoma In Symposium on Kaposis sarcoma. 1962

Hiv associated kaposis sarcoma and classical kaposis sarcoma one disease or two? clinically related immunophenotype studies before and after rifn alpha 2a therapy. Viii International Conference on Aids And The Iii Std World Congress Viii International Conference on Aids And The Iii Std World Congress; Harvard-Amsterdam Conference, Amsterdam, Netherlands, July 19-24, Pagination Varies Viii International Conference on Aids And The Iii Std World Congress: Amsterdam, Netherlands Paper : b107, 1992

Demonstration of the latently-expressed Kaposis sarcoma-associated herpesvirus cyclin D homolog in Kaposis sarcoma by non-isotopic in situ hybridization. Journal of Cutaneous Pathology 24(2): 119, 1997

Intermittent detection of Kaposis Sarcoma-associated herpesvirus in peripheral blood mononuclear cells of HIV-infected Kaposis Sarcoma patients. INFECTIOUS DISEASES SOCIETY OF AMERICA , NATIONAL INSTITUTES OF HEALTH , CENTERS FOR DISEASE CONTROL AND PREVENTION 3rd Conference on retroviruses and opportunistic infections : 123, 1996

PCR in situ for HHV-8 RNA as a differential diagnostic tool between early Kaposis sarcoma and dermatofibroma, and viral localization of positive cells in Kaposis sarcoma. Laboratory Investigation 78(1): 52A, 1998

Diagnostic implication of Kaposis sarcoma-associated herpesvirus-like DNA sequences with special reference to the distinction between spindle cell hemangioendothelioma and Kaposis sarcoma. Journal of Pathology 182(SUPPL ): 24A, 1997

Infection with Kaposis sarcoma-associated herpesvirus and human immunodeficiency virus in relation to the risk and clinical presentation of Kaposis sarcoma in Uganda. British Journal of Cancer 89(3): 502-504, 4 August, 2003

Identification of Kaposis sarcoma-associated herpes-like virus in Kaposis sarcoma lesions from archival material using microdissection and PCR amplification. Modern Pathology 9(1): 130A, 1996

Detection of Kaposis sarcoma associated herpesvirus in saliva of human immunodeficiency virus infected individuals with and without Kaposis sarcoma. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36(0): 178, 1996

Antibody patterns to herpesviruses in kaposis sarcoma part 2 serological association of american kaposis sarcoma with cytomegalovirus. International Journal of Cancer 22(2): 126-131, 1978

Angiosarcoma arising in kaposis sarcoma pleomorphic kaposis sarcoma in a patient with human immunodeficiency virus disease. Journal of the American Academy of Dermatology 24(5 PART 1): 790-792, 1991

Kaposis sarcoma-associated herpesvirus ORF 74 encodes a constitutively active G protein-coupled receptor that is expressed in Kaposis sarcoma and primary effusion lymphoma. Blood 88(10 SUPPL 1 PART 1-2): 205A, 1996

Kaposis sarcoma-associated herpes virus-positive malignant lymphoma in an HIV-negative man with previous Kaposis sarcoma. Blood 88(10 SUPPL 1 PART 1-2): 189B, 1996

Viral latent proteins as targets for Kaposis sarcoma and Kaposis sarcoma-associated herpesvirus induced lymphoma. Current Drug Targets - Infectious Disorders 3(2): 129-135, June, 2003